All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is pleased to present a visual abstract summarizing the key results from a phase I/II trial investigating the combination of azacitidine, venetoclax, and magrolimab for the treatment of patients with newly diagnosed or relapsed/refractory acute myeloid leukemia. These data were recently presented by Naval Daver at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition and offers a rationale for further investigation of magrolimab within triplet combination therapy for patients with acute myeloid leukemia.
To download this visual abstract, click below.Download here
The latest on venetoclax combinations in AML from ASH 2021
The BCL-2 inhibitor, venetoclax, has transformed the treatment landscape for acute myeloid leukemia (AML), particularly in cases where patients are considered ineligible for intensive...
How could new treatment combinations improve outcomes in TP53 mutant AML?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new...
Subscribe to get the best content related to AML delivered to your inbox